IA
CTXR icon

IFP Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

IFP Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53K Sell
4,183
-2,900
-41% -$1.96K ﹤0.01% 4129
2026
Q1 		$6.38K Hold
7,083
– – ﹤0.01% 3391
2025
Q4 		$5.5K Hold
7,083
– – ﹤0.01% 3366
2025
Q3 		$8.78K Hold
7,083
– – ﹤0.01% 2965
2025
Q2 		$11.3K Hold
7,083
– – ﹤0.01% 2839
2025
Q1 		$10.6K Sell
7,083
-33,333
-82% -$79.8K ﹤0.01% 2563
2024
Q4 		$32.8K Buy
40,416
+39,083
+2,932% +$263K ﹤0.01% 2039
2024
Q3 		$16.7K Buy
+1,333
New +$22.4K ﹤0.01% 2216
2023
Q1 		– Sell
-8
Closed -$1K – 3582
2022
Q4 		$1K Hold
8
– – ﹤0.01% 4310
2022
Q3 		$1K Hold
8
– – ﹤0.01% 4527
2022
Q2 		$1K Hold
8
– – ﹤0.01% 4307
2022
Q1 		$1K Buy
+8
New +$316 ﹤0.01% 4307

Other funds holding CTXR

AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

IFP Advisors's CTXR Position: Q2 2026 in Review

IFP Advisors reduced its Citius Pharmaceuticals (CTXR) stake by 41% in Q2 2026, selling an estimated $1.96K and leaving 4,183 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #4129.

IFP Advisors first reported a position in CTXR in Q1 2022 and has held it in 12 quarters since. The position peaked at $32.8K in Q4 2024. 3 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • IFP Advisors held 4,183 shares of Citius Pharmaceuticals worth $2.53K as of Q2 2026.
  • IFP Advisors sold 2,900 Citius Pharmaceuticals shares in Q2 2026, an estimated $1.96K.
  • Citius Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4129 holding.
  • IFP Advisors first reported a position in Citius Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
  • IFP Advisors's Citius Pharmaceuticals position peaked at $32.8K in Q4 2024.
  • 3 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.